![]() | |
| Clinical data | |
|---|---|
| Other names | DOPF; 2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine; 4-(3-Fluoropropyl)-2,5-dimethoxyamphetamine |
| Routes of administration | Unknown1 |
| Pharmacokinetic data | |
| Duration of action | Unknown1 |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H22FNO2 |
| Molar mass | 255.333 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
DOPF, also known as 2,5-dimethoxy-4-(3-fluoropropyl)amphetamine, is a designer drug from the amphetamine and DOx families.1 It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013.1 It has a binding affinity (Ki) of 9 nM at the serotonin receptor 5-HT2A but is not known to have been tested in humans.1 DOPF is a controlled substance in Canada under phenethylamine blanket-ban language.2
References
References
- Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion [Phenethylamine From structure to function] (in German). Nachtschatten Verlag AG. p. 778-780. ISBN 978-3-03788-700-4.
- "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
